EXEL Price Prediction Next Week
Analysis and Insights
Based on the analysis of news sentiment and technical indicators, here is the prediction for EXEL stock:
News Sentiment Analysis:
- Insider sales by key executives, including Patrick J. Haley and Julie Smith, indicate potential lack of confidence in short-term appreciation.
- Mixed institutional investor sentiment, with 273 increasing positions and 238 decreasing, suggests cautious optimism.
Technical Indicators:
- RSI (14): 67.46, indicating overbought conditions.
- MACD: Positive at 1.22, but nearing a potential crossover.
- Stochastic Oscillator: Overbought at 85.25/85.94.
- Fibonacci Levels: Pivot at 37.79, with resistance at 39.03 and support at 36.56.
Price Prediction:
- Target Price: $36.56
- Recommendation: Sell
EXEL Similar Chart Price Prediction
The price of EXEL is predicted to go up -21.08%, based on the high correlation periods with GRVY. The similarity of these two price pattern on the periods is 98.9%.
EXEL
GRVY
Down: -21.08%Similarity: 98.9%
EXEL Revenue Forecast
EXEL EPS Forecast
EXEL FAQs
What is EXEL revenue forecast for next quarter？
EXEL VS S&P500
Cabozantinib has been effective in a variety of cancers, including kidney, liver, and thyroid cancers, and label expansions could further expand the drug's market opportunity.
Partnerships allow Exelixis to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.
Exelixis' collaborations with large pharma players such as Roche/Genentech and Bristol lend credibility to the firm's potential.
EXEL Analyst's Forecast
Derek Archila
Wells Fargo
Buy → Hold
2025-02-24
Price Target
$36
Downside
-3.04%
Wells Fargo downgraded Exelixis to Equal Weight from Overweight with an unchanged price target of $36.
Peter Lawson
Barclays
Hold
2025-02-13
Price Target
$25 → $29
Downside
-15.92%
David Lebowitz
Citigroup
Strong Buy
2025-02-12
Price Target
$38 → $45
Upside
+37.2%
